Ossium Health, Inc. announced that the California Institute of Regenerative Medicine has awarded the company a $3.46M Clinical Stage Research Program grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory acute graft versus host disease.
